Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 29.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 220,500 shares of the biopharmaceutical company's stock after purchasing an additional 50,236 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.07% of Amicus Therapeutics worth $2,077,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in shares of Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after buying an additional 2,856,101 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Amicus Therapeutics in the third quarter worth about $13,530,000. Assenagon Asset Management S.A. increased its position in shares of Amicus Therapeutics by 141.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock valued at $21,765,000 after purchasing an additional 1,192,489 shares during the last quarter. Old West Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 617.2% in the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company's stock valued at $3,636,000 after purchasing an additional 292,976 shares during the period. Finally, PDT Partners LLC purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $2,702,000.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.03 during mid-day trading on Wednesday, hitting $9.14. 561,096 shares of the stock were exchanged, compared to its average volume of 2,282,440. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a 12 month low of $8.78 and a 12 month high of $14.02. The business has a fifty day moving average price of $9.53 and a 200 day moving average price of $10.39. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of -50.81, a PEG ratio of 1.51 and a beta of 0.61.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on FOLD shares. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Guggenheim increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.